Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2390]

Radioembolisation with chemotherapy for colorectal liver metastases

Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA

Radioembolisation with chemotherapy for colorectal liver metastases ( Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA )

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

MRD-guided therapy debate

Prof Ola Landgren - University of Miami, Miami, USA

MRD-guided therapy debate ( Prof Ola Landgren - University of Miami, Miami, USA )

Cabozantinib in combination with atezolizumab in patients with mCRPC

Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty...

Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, USA )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

More from ecancer